title: Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
abstract: Interest exists in identifying the factors that specifically contribute to the increased prevalence of cardiovascular disease observed in psychiatric disease. The apolipoprotein-E (APOE) gene codes for a protein that has a key role in metabolism of cholesterol and triglycerides, with increased levels of apoE found in specific areas of post-mortem schizophrenic brains. This study investigated whether apoE variants influence the prevalence of cardiovascular risk factors (obesity, diabetes and dyslipidaemia), in patients receiving antipsychotic treatment, due to extension of the risk seen in the general population, but also due to the role of the APOE gene in mediating antipsychotic-induced side effects. Seven polymorphisms (rs741780, rs483082, rs429358, rs7412, rs10119, rs439401 and rs405509) were genotyped in 427 American Caucasian patients who were either receiving, or had been prescribed risperidone. Our results support the hypothesis that APOE gene variants influence the prevalence of diabetes and possibly overweight in psychiatric patients. Unfortunately, due to the cross sectional nature of this study, the contribution of antipsychotic treatment was not determined. These associations warrant prospective study to assess interaction between APOE gene variants and the propensity of antipsychotics to induce cardiovascular risk factors.
authors.affiliation: Department of Psychological Medicine, Institute of Psychiatry, King's College, 1, Windsor Walk, PO51, London SE5 8AF, UK.
authors.forename: D
authors.initials: D
authors.lastname: Clark
authors.forename: O A
authors.initials: OA
authors.lastname: Skrobot
authors.forename: I
authors.initials: I
authors.lastname: Adebiyi
authors.forename: M T
authors.initials: MT
authors.lastname: Susce
authors.forename: J
authors.initials: J
authors.lastname: de Leon
authors.forename: Ai F
authors.initials: AF
authors.lastname: Blakemore
authors.forename: M J
authors.initials: MJ
authors.lastname: Arranz
mesh_terms: D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001057:Apolipoproteins E / Q000235:genetics*; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics; D006580:Genetic Carrier Screening; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005838:Genotype; D006720:Homozygote; D006801:Humans; D006937:Hypercholesterolemia / Q000235:genetics; D006949:Hyperlipidemias / Q000235:genetics; D006973:Hypertension / Q000235:genetics; D009765:Obesity / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics*
chemical_list: D014150:Antipsychotic Agents; D001057:Apolipoproteins E; D018967:Risperidone